Publications by authors named "I Niewold"
Article Synopsis
- CD21 B cells are a type of immune cell that show increased numbers in patients with rheumatic diseases, including common autoimmune conditions and autoinflammatory diseases like axial spondyloarthritis.
- Researchers studied the B-cell receptor repertoire using next-generation sequencing to understand the origins and relationships of these CD21 B cells and their development into more mutated forms (like plasmablasts) in patients compared to healthy individuals.
- The findings suggest that expanded CD27CD21 B cells in autoimmune and autoinflammatory patients may play a significant role in contributing to harmful immune responses associated with these diseases.
Background: Although B-cell depleting therapy in rheumatoid arthritis (RA) is clearly effective, response is variable and does not correlate with B cell depletion itself.
Methods: The B-cell receptor (BCR) repertoire was prospectively analyzed in peripheral blood samples of twenty-eight RA patients undergoing rituximab therapy. Timepoints of achieved BCR-depletion and -repopulation were defined based on the percentage of unmutated BCRs in the repertoire.
Objectives: To characterize the T cell receptor (TCRβ) repertoire in peripheral blood and muscle tissues of treatment naïve patients with newly diagnosed idiopathic inflammatory myopathies (IIMs).
Methods: High throughput RNA sequencing of the TCRβ chain was performed in peripheral blood and muscle tissue in twenty newly-diagnosed treatment-naïve IIM patients (9 DM, 5 NM/OM, 5 IMNM and 1 ASyS) and healthy controls. Results thereof were correlated with markers of disease activity.
The immunopathophysiological mechanisms underlying chronic inflammatory demyelinating polyneuropathy (CIDP) in an individual patient are largely unknown. Better understanding of these mechanisms may aid development of biomarkers and targeted therapies. Both B- and T-cell dominant mechanisms have been implicated.
View Article and Find Full Text PDFArticle Synopsis
- The study explores B-cell receptor (BcR) characteristics in muscle tissues and peripheral blood of patients with idiopathic inflammatory myopathies (IIMs) and assesses their correlation with clinical response to IVIG treatment.
- Nineteen treatment-naive IIM patients underwent RNA-based BcR repertoire sequencing before and after IVIG treatment, with results linked to clinical improvement scores.
- The findings suggest that a higher frequency of specific BcR clones in peripheral blood prior to treatment is associated with better treatment outcomes and may influence the effectiveness of IVIG therapy.